708 related articles for article (PubMed ID: 30298067)
1. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.
Rosewell Shaw A; Suzuki M
Front Immunol; 2018; 9():2103. PubMed ID: 30298067
[TBL] [Abstract][Full Text] [Related]
2. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
4. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
5. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
Tang XY; Ding YS; Zhou T; Wang X; Yang Y
Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
[TBL] [Abstract][Full Text] [Related]
7. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
Crupi MJF; Bell JC; Singaravelu R
Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
[TBL] [Abstract][Full Text] [Related]
8. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
9. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
10. Prospects for combined use of oncolytic viruses and CAR T-cells.
Ajina A; Maher J
J Immunother Cancer; 2017 Nov; 5(1):90. PubMed ID: 29157300
[TBL] [Abstract][Full Text] [Related]
11. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
[No Abstract] [Full Text] [Related]
12. Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.
Li Y; Xiao F; Zhang A; Zhang D; Nie W; Xu T; Han B; Seth P; Wang H; Yang Y; Wang L
Cell Immunol; 2020 Feb; 348():104041. PubMed ID: 31983398
[TBL] [Abstract][Full Text] [Related]
13. [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].
Kochneva GV; Sivolobova GF; Tkacheva AV; Gorchakov AA; Kulemzin SV
Mol Biol (Mosk); 2020; 54(1):3-16. PubMed ID: 32163385
[TBL] [Abstract][Full Text] [Related]
14. Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy.
McGrath K; Dotti G
Hum Gene Ther; 2021 Feb; 32(3-4):150-157. PubMed ID: 33349123
[TBL] [Abstract][Full Text] [Related]
15. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
Watanabe N; McKenna MK; Rosewell Shaw A; Suzuki M
Mol Ther; 2021 Feb; 29(2):505-520. PubMed ID: 33130314
[TBL] [Abstract][Full Text] [Related]
16. Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses.
Zarezadeh Mehrabadi A; Roozbahani F; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Esmaeili Gouvarchin Ghaleh H
World J Surg Oncol; 2022 Jan; 20(1):16. PubMed ID: 35027068
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.
Rezaei R; Esmaeili Gouvarchin Ghaleh H; Farzanehpour M; Dorostkar R; Ranjbar R; Bolandian M; Mirzaei Nodooshan M; Ghorbani Alvanegh A
Cancer Gene Ther; 2022 Jun; 29(6):647-660. PubMed ID: 34158626
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.
Heidbuechel JPW; Engeland CE
J Hematol Oncol; 2021 Apr; 14(1):63. PubMed ID: 33863363
[TBL] [Abstract][Full Text] [Related]
19. Development of oncolytic viruses for cancer therapy.
Abd-Aziz N; Poh CL
Transl Res; 2021 Nov; 237():98-123. PubMed ID: 33905949
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Virotherapy and the Tumor Microenvironment.
Berkey SE; Thorne SH; Bartlett DL
Adv Exp Med Biol; 2017; 1036():157-172. PubMed ID: 29275471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
